Search research articles
Contact Us
Filters
Showing results (61-70 of 126) with videos related to
Page
of 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Helen Dearden, Lewis Au, Daniel Y Wang, et al.
British Journal of Cancer
|
March 22, 2017
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
Samantha Bowyer, Prashanth Prithviraj, Paul Lorigan, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
The New England Journal of Medicine
|
September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer, Axel Hauschild, Mario Santinami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina V Long, Caroline Robert, Marcus O Butler, et al.
The New England Journal of Medicine
|
September 30, 2014
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma
James Larkin, Paolo A Ascierto, Brigitte Dréno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 23, 2021
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Paolo A Ascierto, Brigitte Dréno, James Larkin, et al.
The Lancet. Oncology
|
April 18, 2025
Clinical validation of droplet digital PCR assays in detecting BRAF<sup>V600</sup>-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Mahrukh M Syeda, Georgina V Long, James Garrett, et al.
Journal of Translational Medicine
|
October 26, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Domenico Mallardo, Rachel Woodford, Alexander M Menzies, et al.
Melanoma Research
|
May 17, 2019
Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program
Salvador Martin-Algarra, Rebecca Hinshelwood, Soizick Mesnage, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 126) with videos related to
Sort By:
Page
of 13
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Helen Dearden, Lewis Au, Daniel Y Wang, et al.
British Journal of Cancer
|
March 22, 2017
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
Samantha Bowyer, Prashanth Prithviraj, Paul Lorigan, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
The New England Journal of Medicine
|
September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer, Axel Hauschild, Mario Santinami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina V Long, Caroline Robert, Marcus O Butler, et al.
The New England Journal of Medicine
|
September 30, 2014
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma
James Larkin, Paolo A Ascierto, Brigitte Dréno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 23, 2021
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Paolo A Ascierto, Brigitte Dréno, James Larkin, et al.
The Lancet. Oncology
|
April 18, 2025
Clinical validation of droplet digital PCR assays in detecting BRAF<sup>V600</sup>-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Mahrukh M Syeda, Georgina V Long, James Garrett, et al.
Journal of Translational Medicine
|
October 26, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Domenico Mallardo, Rachel Woodford, Alexander M Menzies, et al.
Melanoma Research
|
May 17, 2019
Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program
Salvador Martin-Algarra, Rebecca Hinshelwood, Soizick Mesnage, et al.
Page
of 13